Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Recent outbreaks of avian influenza and ongoing virus reassortment have drawn focus on spill-over infections. The increase in human infections with highly pathogenic avian influenza H5N6 virus and its high fatality rate posed a potential threat, necessitating the search for a more effective treatment.
METHODS: Longitudinal clinical data and specimens were collected from five H5N6 patients after admission. All patients received antiviral treatment of either sequential monotherapy of oseltamivir and baloxavir or the two drugs in combination. Severity of illness; viral load in sputum, urine, and blood; and cytokine levels in serum and sputum were serially analyzed.
FINDINGS: All patients developed acute respiratory distress syndrome (ARDS) and viral sepsis within 1 week after disease onset. When delayed oseltamivir showed poor effects, baloxavir was administered and rapidly decreased viral load. In addition, levels of IL-18, M-CSF, IL-6, and HGF in sputum and Mig and IL-18 in serum that reflected ARDS and sepsis deterioration, respectively, were also reduced with baloxavir usage. However, three patients eventually died from exacerbation of underlying disease and secondary bacterial infection. Nonsurvivors had more severe extrapulmonary organ dysfunction and insufficient H5N6 virus-specific antibody response.
CONCLUSIONS: For critical human cases of H5N6 infection, baloxavir demonstrated effects on viral load and pulmonary/extrapulmonary cytokines, even though treatment was delayed. Baloxavir could be regarded as a first-line treatment to limit continued viral propagation, with potential future application in avian influenza human infections and poultry workers exhibiting influenza-like illness.
FUNDING: This work was funded by the National Natural Science Foundation of China (81761128014).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Med (New York, N.Y.) - 5(2024), 1 vom: 12. Jan., Seite 32-41.e5 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guan, Wenda [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.01.2024 Date Revised 15.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.medj.2023.11.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365613290 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365613290 | ||
| 003 | DE-627 | ||
| 005 | 20240115231944.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.medj.2023.11.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1260.xml |
| 035 | |a (DE-627)NLM365613290 | ||
| 035 | |a (NLM)38070511 | ||
| 035 | |a (PII)S2666-6340(23)00361-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guan, Wenda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2024 | ||
| 500 | |a Date Revised 15.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Recent outbreaks of avian influenza and ongoing virus reassortment have drawn focus on spill-over infections. The increase in human infections with highly pathogenic avian influenza H5N6 virus and its high fatality rate posed a potential threat, necessitating the search for a more effective treatment | ||
| 520 | |a METHODS: Longitudinal clinical data and specimens were collected from five H5N6 patients after admission. All patients received antiviral treatment of either sequential monotherapy of oseltamivir and baloxavir or the two drugs in combination. Severity of illness; viral load in sputum, urine, and blood; and cytokine levels in serum and sputum were serially analyzed | ||
| 520 | |a FINDINGS: All patients developed acute respiratory distress syndrome (ARDS) and viral sepsis within 1 week after disease onset. When delayed oseltamivir showed poor effects, baloxavir was administered and rapidly decreased viral load. In addition, levels of IL-18, M-CSF, IL-6, and HGF in sputum and Mig and IL-18 in serum that reflected ARDS and sepsis deterioration, respectively, were also reduced with baloxavir usage. However, three patients eventually died from exacerbation of underlying disease and secondary bacterial infection. Nonsurvivors had more severe extrapulmonary organ dysfunction and insufficient H5N6 virus-specific antibody response | ||
| 520 | |a CONCLUSIONS: For critical human cases of H5N6 infection, baloxavir demonstrated effects on viral load and pulmonary/extrapulmonary cytokines, even though treatment was delayed. Baloxavir could be regarded as a first-line treatment to limit continued viral propagation, with potential future application in avian influenza human infections and poultry workers exhibiting influenza-like illness | ||
| 520 | |a FUNDING: This work was funded by the National Natural Science Foundation of China (81761128014) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Translation to patients | |
| 650 | 4 | |a avian influenza A(H5N6) virus | |
| 650 | 4 | |a baloxavir marboxil | |
| 650 | 4 | |a cytokines | |
| 650 | 4 | |a sepsis | |
| 650 | 4 | |a viral load | |
| 650 | 7 | |a baloxavir |2 NLM | |
| 650 | 7 | |a 4G86Y4JT3F |2 NLM | |
| 650 | 7 | |a Oseltamivir |2 NLM | |
| 650 | 7 | |a 20O93L6F9H |2 NLM | |
| 650 | 7 | |a Interleukin-18 |2 NLM | |
| 650 | 7 | |a Dibenzothiepins |2 NLM | |
| 650 | 7 | |a Morpholines |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a Triazines |2 NLM | |
| 700 | 1 | |a Qu, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Lihan |e verfasserin |4 aut | |
| 700 | 1 | |a Mai, Kailin |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Weiqi |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Zhengshi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Liping |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Ji |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jiawei |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Pei |e verfasserin |4 aut | |
| 700 | 1 | |a Weng, Yunceng |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Minfei |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Peikun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jinchao |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Chuanmeizi |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Xiao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Chunguang |e verfasserin |4 aut | |
| 700 | 1 | |a Ling, Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Le, Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhan, Yangqing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yimin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xiaoqing |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Heyan |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Ziqi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Hongxia |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Qiubao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wenjie |e verfasserin |4 aut | |
| 700 | 1 | |a He, Jiayang |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Teng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Nanshan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Zifeng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Med (New York, N.Y.) |d 2020 |g 5(2024), 1 vom: 12. Jan., Seite 32-41.e5 |w (DE-627)NLM314117954 |x 2666-6340 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2024 |g number:1 |g day:12 |g month:01 |g pages:32-41.e5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.medj.2023.11.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2024 |e 1 |b 12 |c 01 |h 32-41.e5 | ||